Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free ...
CheckMate 577 study on nivolumab for gastro-oesophageal cancer ...
Checkmate 577 - Is Nivolumab adjuvant the standard of care in esophagus ...
Adherence to CheckMate 577 Within a Community Health Care System in the ...
Expanded efficacy and safety analyses from CheckMate 577
CheckMate 577: nivolumabe adjuvante após quimioradioterapia e cirurgia ...
CheckMate 577: Adjuvant Nivolumab Plus Neoadjuvant Chemoradiotherapy ...
CheckMate 577: final OS results of adjuvant nivolumab in EC/GEJC ...
CheckMate 77T Trial: Perioperative Nivolumab Plus Chemotherapy in Stage ...
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
Subcutaneous Nivolumab Preferred Over IV for ccRCC: PROs From CheckMate ...
陳奇勳教授專訪 | CheckMate -577數據更新證實長期獲益，納武利尤單抗問鼎食管癌輔助治療 - 每日頭條
(PDF) First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate ...
ESOPEC, CheckMate 577, and Neo-AEGIS: Breakthroughs in Esophageal ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 ...
Hematología y Oncología: ASCO 2015 - CheckMate 067: Improved PFS with ...
CheckMate 511 NIVO/IPI Dosing - Slideset Download - Clinical Oncology ...
(PDF) Checkmate 274 trial: Is Nivolumab the new standard in adjuvant ...
CheckMate 9LA: 4-Yr Update of First-line Nivolumab + Ipilimumab + CT vs ...
CheckMate 77T Trial of Perioperative Nivolumab Generates EFS Benefit in ...
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent ...
点评CROSS研究10年结果及CheckMate 577
Final CheckMate 9ER data show long-term efficacy of nivolumab ...
CheckMate 77T QOL Data Further Support Perioperative Nivolumab in ...
Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early ...
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and ...
CheckMate 274: 5-year data confirm durable benefit with nivolumab ...
Supplemental Materials for CheckMate 171: A phase 2 trial of nivolumab ...
CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as ...
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 ...
CheckMate 017/057的五年生存结果：Nivolumab在二线非小细胞肺癌治疗中优于多西他赛 - 精选 - 阳光肺科
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
傅剑华教授：CheckMate-577研究满载而归，开辟食管癌免疫辅助治疗全新道路_武利尤_患者_手术
Journal of Clinical Images and Medical Case Reports
(PDF) Nivolumab adjuvant therapy for esophageal cancer: a review based ...
VÑ CheckMate-577, NeoAd CáEsóf UGE, R0, ady [Nivolumab vs Placebo ...
Adjuvant Nivolumab in Patients with Resected Esophageal or GEJ Cancer ...
Milestones of PD-1 inhibition in gastric and esophageal cancer ...
DailyMed - OPDIVO QVANTIG- nivolumab and hyaluronidase-nvhy injection ...
CheckMate-577 opens a new perspective for the treatment of esophageal ...
Adjuvant nivolumab in resected esophageal or gastroesophageal junction ...
CheckMate-577: Nivolumab Adjuvant Therapy in Patients with Resected ...
Ca. gastroesofágico y UGE: COFEPRIS aprobó nivolumab adyuvante y en ...
食道がんへの術後ニボルマブ、長期追跡でもベネフィット示す（CheckMate 577）／ASCO2025｜医師向け医療ニュースはケアネット
Nivolumab for perioperative esophageal and gastroesophageal cancer ...
FDA Approval Summary: Nivolumab for the adjuvant treatment of adults ...
Nivolumab may be ‘new standard’ in esophageal, gastroesophageal ...
Q&A with Ronan J. Kelly: FDA Approval of Immunotherapy Drug Nivolumab ...
局部晚期食管癌治疗指南更新解读 - 高龄备孕网
食道がんのニボルマブ術後補助療法、追加解析の成績（CheckMate 577）／ASCO2021｜医師向け医療ニュースはケアネット
陈奇勋教授：CheckMate-577 研究独树一帜，纳武利尤单抗引领食管癌辅助治疗全新格局_患者_手术_免疫
2021食管癌诊疗年度盘点：免疫时代的治疗选择_研究_患者_化疗
Nivolumab Improves Outcomes in Esophageal/GEJ Cancer | Targeted ...
Nivolumab plus chemotherapy in first-line metastatic non-small-cell ...
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma ...
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung ...
Oncology me
PD-1最新临床进展大公开|NSCLC|ORR|PFS|临床|肺癌|化疗|-健康界
Highlights on 1L nivolumab + chemo for metastatic urothelial carcinoma ...
(PDF) A population-based study in resected esophageal or ...
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus ...
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes ...
Extended CheckMate-274 Data Reinforce the Benefit of Adjuvant Nivolumab ...
Table 1 from Nivolumab Versus Docetaxel in Previously Treated Patients ...
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With ...
【4332】ASCO|Ronan Kelly教授深度解析CheckMate 577长随访数据，展望食管癌围手术期免疫治疗未来之路医药新闻 ...
Dr. Kelly on the Rationale for the CheckMate-577 Trial in Esophageal ...
Nivolumab with or without ipilimumab in patients with recurrent or ...
Nivolumab in metastatic urothelial carcinoma after platinum therapy ...
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab ...
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
Evaluation of Two Dosing Regimens for Nivolumab in Combination With ...
A population-based study in resected esophageal or gastroesophageal ...
Checkpoint Inhibitors Gain Traction in the Frontline Setting for ...
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal ...
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC ...
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced ...
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With ...
Highlights zu den Tumoren des oberen Gastrointestinaltrakts - Onkologie ...
ESMO Virtual Congress 2020: A Phase 3, Randomized, Double-Blind Trial ...
ESMO 2022: Tumor and Immune Features Associated with Disease-Free ...
ASCO GU Symposium 2024 Coverage | GU Oncology Now
